Oramed Patent Allowed in the U.S. for Key Aspect of Its Oral Delivery Technology
NEW YORK, March 28, 2019 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its U.S. patent for the technology “Protease Inhibitor-Containing Compositions, Compositions Comprising Same, and Methods for Producing and using Same” has been allowed by the United […]
